艾乐明^®（巴瑞替尼片）

巴瑞替尼在日本 NNS、SAVI 和 AGS 患者中的疗效和安全性

Efficacy and safety of baricitinib in Japanese patients with NNS, SAVI, and AGS

发表日期：2023-04-22

巴瑞替尼联合外用皮质类固醇治疗中重度特应性皮炎成人患者的长期疗效（长达 68 周）：源自研究 BREEZE-AD7 的治疗反应者、部分反应者和无反应者分析

Long-Term Efficacy (up to 68 Weeks) of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Analysis of Treatment Responders, Partial Responders and Nonresponders Originating from Study BREEZE-AD7

发表日期：2023-05-01

在一项随机试验中，接受长达 104 周治疗的中度至重度特应性皮炎成人中，巴瑞替尼治疗的医生和患者报告结局持续改善

Maintained Improvement in Physician- and Patient-Reported Outcomes with Baricitinib in Adults with Moderate-to-Severe Atopic Dermatitis who were Treated for up to 104 Weeks in a Randomized Trial

发表日期：2023-04-05

疼痛和疾病活动对疲劳改善的相对影响：两项 巴瑞替尼 3 期临床试验的结果

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results from Two Baricitinib Phase 3 Clinical Trials

发表日期：2023-04-01

巴瑞替尼联合外用皮质类固醇治疗对外用皮质类固醇反应不足的中重度特应性皮炎儿科患者的疗效和安全性：3 期、随机、双盲、安慰剂对照的结果

Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled

发表日期：2023-03-31

巴瑞替尼 治疗斑秃的两项 3 期试验

Two Phase 3 Trials of Baricitinib for Alopecia Areata

发表日期：2022-05-05

在美国临床试验 (BREEZE-AD5) 中使用巴瑞替尼治疗的特应性皮炎患者的日常日记中报告的症状缓解起效时间

Onset of Symptom Relief Reported in Daily Diaries in Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)

发表日期：2022-01-28

在巴瑞替尼 3 期试验中，瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的贡献。

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.

发表日期：2022-01-18